Skip to content

The efficacy and safety of short-term deep sedation strategy based on analgesia in preventing cerebral dysfunction in aneurysmal subarachnoid hemorrhage: a randomized controlled trial

The efficacy and safety of short-term deep sedation strategy based on analgesia in preventing cerebral dysfunction in aneurysmal subarachnoid hemorrhage: a randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800020268
Enrollment
Unknown
Registered
2018-12-21
Start date
2018-12-30
Completion date
Unknown
Last updated
2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aneurysmal subarachnoid hemorrhage

Interventions

Group 1:Deep sedation
Group 2:Light sedation

Sponsors

The First Affiliated Hospital of Xinjiang Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 65 years old; 2. High level of diagnostic criteria for aneurysmal subarachnoid hemorrhage (Hunt - Hess classification III, IV); 3. Mechanical ventilation time > 72h; 4. The patient himself or his legally authorized representative is willing to provide the informed consent (ICF); 5. BMI < 35kg/m2.

Exclusion criteria

Exclusion criteria: 1. Severe brain stem failure: bilateral pupil dilation and fixation, GCS=3 score, spontaneous respiratory arrest, hypotension, cardiac arrest; 2. Epileptic status; 3. Moderate to severe renal impairment (creatinine clearance rate less than 50ml/min); 4. Allergy to opioids; 5. Drug use history of monoamine oxidase inhibitor within 14 days; 6. Neuromuscular blockers are required to improve mechanical ventilation; 7. Failure to effectively control local or systemic bacterial infection in the acute stage; 8. The end stage of chronic diseases; 9. Lactation or pregnancy.

Design outcomes

Primary

MeasureTime frame
The incidence of early cerebral vasospasm;The incidence of delayed cerebral ischemia;

Secondary

MeasureTime frame
SIRS score;Difference of catecholamine;Incidence of rebleeding;Hemodynamic monitoring parameters of Picco;GCS score;Length of stay in the ICU;Length ofmechanical ventilation;Arterial blood PaCO2;28-day mortality;VAP incidence;Neurological function prognosis score (GOS) at 28 days.;

Countries

China

Contacts

Public ContactXiaopeng Li

The First Affiliated Hospital of Xinjiang Medical University

lixiaopeng1229@163.com+86 13579806557

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026